FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038984648> ?p ?o ?g. }

• W2038984648 endingPage "453" @default.
• W2038984648 startingPage "446" @default.
• W2038984648 abstract "Phenylacetic acid (PAA) is the active moiety in sodium phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB, HPN-100). Both are approved for treatment of urea cycle disorders (UCDs) - rare genetic disorders characterized by hyperammonemia. PAA is conjugated with glutamine in the liver to form phenylacetyleglutamine (PAGN), which is excreted in urine. PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously. Therefore, we have investigated the relationship between PAA levels and neurological AEs in patients treated with these PAA pro-drugs as well as approaches to identifying patients most likely to experience high PAA levels.The relationship between nervous system AEs, PAA levels and the ratio of plasma PAA to PAGN were examined in 4683 blood samples taken serially from: [1] healthy adults [2], UCD patients of ≥ 2 months of age, and [3] patients with cirrhosis and hepatic encephalopathy (HE). The plasma ratio of PAA to PAGN was analyzed with respect to its utility in identifying patients at risk of high PAA values.Only 0.2% (11) of 4683 samples exceeded 500 μg/ml. There was no relationship between neurological AEs and PAA levels in UCD or HE patients, but transient AEs including headache and nausea that correlated with PAA levels were observed in healthy adults. Irrespective of population, a curvilinear relationship was observed between PAA levels and the plasma PAA:PAGN ratio, and a ratio>2.5 (both in μg/mL) in a random blood draw identified patients at risk for PAA levels>500 μg/ml.The presence of a relationship between PAA levels and reversible AEs in healthy adults but not in UCD or HE patients may reflect intrinsic differences among the populations and/or metabolic adaptation with continued dosing. The plasma PAA:PAGN ratio is a functional measure of the rate of PAA metabolism and represents a useful dosing biomarker." @default.
• W2038984648 created "2016-06-24" @default.
• W2038984648 creator A5000261070 @default.
• W2038984648 creator A5001184377 @default.
• W2038984648 creator A5002194433 @default.
• W2038984648 creator A5003908509 @default.
• W2038984648 creator A5011564602 @default.
• W2038984648 creator A5012984200 @default.
• W2038984648 creator A5014706317 @default.
• W2038984648 creator A5015634342 @default.
• W2038984648 creator A5017857179 @default.
• W2038984648 creator A5020093708 @default.
• W2038984648 creator A5021954687 @default.
• W2038984648 creator A5021956757 @default.
• W2038984648 creator A5023226601 @default.
• W2038984648 creator A5025057960 @default.
• W2038984648 creator A5028429462 @default.
• W2038984648 creator A5031776799 @default.
• W2038984648 creator A5032043915 @default.
• W2038984648 creator A5032217427 @default.
• W2038984648 creator A5034064460 @default.
• W2038984648 creator A5039069406 @default.
• W2038984648 creator A5043752774 @default.
• W2038984648 creator A5050648441 @default.
• W2038984648 creator A5052306408 @default.
• W2038984648 creator A5054026499 @default.
• W2038984648 creator A5054723227 @default.
• W2038984648 creator A5076734566 @default.
• W2038984648 creator A5080080523 @default.
• W2038984648 creator A5091130570 @default.
• W2038984648 date "2013-12-01" @default.
• W2038984648 modified "2023-10-10" @default.
• W2038984648 title "Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio" @default.
• W2038984648 cites W1487338389 @default.
• W2038984648 cites W1488281450 @default.
• W2038984648 cites W1496144666 @default.
• W2038984648 cites W170507614 @default.
• W2038984648 cites W1926394072 @default.
• W2038984648 cites W1964203649 @default.
• W2038984648 cites W1965443388 @default.
• W2038984648 cites W1971793083 @default.
• W2038984648 cites W1972978214 @default.
• W2038984648 cites W1980718219 @default.
• W2038984648 cites W1993148008 @default.
• W2038984648 cites W2002801680 @default.
• W2038984648 cites W2014239161 @default.
• W2038984648 cites W2026033409 @default.
• W2038984648 cites W2031442399 @default.
• W2038984648 cites W2033939771 @default.
• W2038984648 cites W2035588879 @default.
• W2038984648 cites W2055771981 @default.
• W2038984648 cites W2059350747 @default.
• W2038984648 cites W2072873237 @default.
• W2038984648 cites W2090290516 @default.
• W2038984648 cites W2097097560 @default.
• W2038984648 cites W2099049651 @default.
• W2038984648 cites W2103213382 @default.
• W2038984648 cites W2114252949 @default.
• W2038984648 cites W2132775040 @default.
• W2038984648 cites W2137529804 @default.
• W2038984648 cites W2149860264 @default.
• W2038984648 cites W3120435183 @default.
• W2038984648 cites W4240751953 @default.
• W2038984648 cites W4252113783 @default.
• W2038984648 doi "https://doi.org/10.1016/j.ymgme.2013.09.017" @default.
• W2038984648 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4108288" @default.
• W2038984648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24144944" @default.
• W2038984648 hasPublicationYear "2013" @default.
• W2038984648 type Work @default.
• W2038984648 sameAs 2038984648 @default.
• W2038984648 citedByCount "29" @default.
• W2038984648 countsByYear W20389846482014 @default.
• W2038984648 countsByYear W20389846482015 @default.
• W2038984648 countsByYear W20389846482016 @default.
• W2038984648 countsByYear W20389846482017 @default.
• W2038984648 countsByYear W20389846482018 @default.
• W2038984648 countsByYear W20389846482019 @default.
• W2038984648 countsByYear W20389846482021 @default.
• W2038984648 countsByYear W20389846482022 @default.
• W2038984648 countsByYear W20389846482023 @default.
• W2038984648 crossrefType "journal-article" @default.
• W2038984648 hasAuthorship W2038984648A5000261070 @default.
• W2038984648 hasAuthorship W2038984648A5001184377 @default.
• W2038984648 hasAuthorship W2038984648A5002194433 @default.
• W2038984648 hasAuthorship W2038984648A5003908509 @default.
• W2038984648 hasAuthorship W2038984648A5011564602 @default.
• W2038984648 hasAuthorship W2038984648A5012984200 @default.
• W2038984648 hasAuthorship W2038984648A5014706317 @default.
• W2038984648 hasAuthorship W2038984648A5015634342 @default.
• W2038984648 hasAuthorship W2038984648A5017857179 @default.
• W2038984648 hasAuthorship W2038984648A5020093708 @default.
• W2038984648 hasAuthorship W2038984648A5021954687 @default.
• W2038984648 hasAuthorship W2038984648A5021956757 @default.
• W2038984648 hasAuthorship W2038984648A5023226601 @default.
• W2038984648 hasAuthorship W2038984648A5025057960 @default.
• W2038984648 hasAuthorship W2038984648A5028429462 @default.
• W2038984648 hasAuthorship W2038984648A5031776799 @default.
• W2038984648 hasAuthorship W2038984648A5032043915 @default.

• next